Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.

Mathur A, Ware C, Davis L, Gazdar A, Pan BS, Lutterbach B.

PLoS One. 2014 Jun 26;9(6):e98515. doi: 10.1371/journal.pone.0098515. eCollection 2014.


Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.


Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.

Northrup AB, Katcher MH, Altman MD, Chenard M, Daniels MH, Deshmukh SV, Falcone D, Guerin DJ, Hatch H, Li C, Lu W, Lutterbach B, Allison TJ, Patel SB, Reilly JF, Reutershan M, Rickert KW, Rosenstein C, Soisson SM, Szewczak AA, Walker D, Wilson K, Young JR, Pan BS, Dinsmore CJ.

J Med Chem. 2013 Mar 28;56(6):2294-310. doi: 10.1021/jm301619u. Epub 2013 Mar 18.


Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, Deshmukh SV, Pan BS, Marshall CG, Lu W, Altman MD, Dahlberg WK, Davis L, Falcone D, Gabarda AE, Hang G, Hatch H, Holmes R, Kunii K, Lumb KJ, Lutterbach B, Mathvink R, Nazef N, Patel SB, Qu X, Reilly JF, Rickert KW, Rosenstein C, Soisson SM, Spencer KB, Szewczak AA, Walker D, Wang W, Young J, Zeng Q.

J Med Chem. 2011 Jun 23;54(12):4092-108. doi: 10.1021/jm200112k. Epub 2011 May 24.


Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.

Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, Lutterbach BA, Chi A, Paweletz C, Allison T, Yan Y, Munshi SK, Klippel A, Kraus M, Bobkova EV, Deshmukh S, Xu Z, Mueller U, Szewczak AA, Pan BS, Richon V, Pollock R, Blume-Jensen P, Northrup A, Andersen JN.

J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30.


Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M.

Am J Pathol. 2010 Jul;177(1):415-23. doi: 10.2353/ajpath.2010.090863. Epub 2010 May 20.


MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.

Cancer Res. 2010 Feb 15;70(4):1524-33. doi: 10.1158/0008-5472.CAN-09-2541. Epub 2010 Feb 9.


High-throughput analysis of HGF-stimulated cell scattering.

Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA.

J Biomol Screen. 2008 Oct;13(9):847-54. doi: 10.1177/1087057108324497. Epub 2008 Sep 23.


FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B.

Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229. Erratum in: Cancer Res. 2008 May 1;68(9):3550.


Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS.

Cancer Res. 2007 Mar 1;67(5):2081-8. Erratum in: Cancer Res. 2007 Apr 15;67(8):3987.


RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.

Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL, Luce KS, Irvin BJ, Cleary ML, Brandt SJ, Hiebert SW.

Oncogene. 2006 Sep 21;25(42):5777-86. Epub 2006 May 1.


The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW.

Mol Cell Biol. 2003 Jan;23(2):607-19.


Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.

Barseguian K, Lutterbach B, Hiebert SW, Nickerson J, Lian JB, Stein JL, van Wijnen AJ, Stein GS.

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15434-9. Epub 2002 Nov 11.


Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.

Heibert SW, Lutterbach B, Durst K, Wang L, Linggi B, Wu S, Wood L, Amann J, King D, Hou Y.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S31-4. Review.


Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins.

Hiebert SW, Lutterbach B, Amann J.

Curr Opin Hematol. 2001 Jul;8(4):197-200. Review.


ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.

Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW.

Mol Cell Biol. 2001 Oct;21(19):6470-83.


B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation.

Gregory MA, Xiao Q, Cornwall GA, Lutterbach B, Hann SR.

Oncogene. 2000 Oct 5;19(42):4886-95.


Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.

Lutterbach B, Hiebert SW.

Gene. 2000 Mar 21;245(2):223-35. Review.


The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein.

Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, Lutterbach B, Hiebert SW, Licht JD.

Mol Cell Biol. 2000 Mar;20(6):2075-86.


Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle.

Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N, Hiebert SW.

J Biol Chem. 2000 Feb 4;275(5):3438-45.


A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia.

Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW.

J Biol Chem. 2000 Jan 7;275(1):651-6.


The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

Lutterbach B, Hou Y, Durst KL, Hiebert SW.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12822-7.


Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR, Hiebert SW.

Mol Cell Biol. 1999 Oct;19(10):6566-74.


ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors.

Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW.

Mol Cell Biol. 1998 Dec;18(12):7176-84.


Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation.

Lutterbach B, Hann SR.

Oncogene. 1997 Feb 27;14(8):967-75.


YACs and the C. elegans genome.

Coulson A, Kozono Y, Lutterbach B, Shownkeen R, Sulston J, Waterston R.

Bioessays. 1991 Aug;13(8):413-7. Review.


Supplemental Content

Loading ...
Support Center